An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.
Li L, Xiao S, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Zhang X, Chang Y, Nan F, Yan J, Li Z, Shi M, Young KH, Zhang M.
Li L, et al. Among authors: zhang l, zhang m, zhang x.
Oncotarget. 2018 Jan 2;9(22):16213-16219. doi: 10.18632/oncotarget.23806. eCollection 2018 Mar 23.
Oncotarget. 2018.
PMID: 29662638
Free PMC article.